​
​

Aura Biosciences (AURA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

AURA Stock Forecast

Aura Biosciences stock forecast is as follows: an average price target of $24.75 (represents a 177.47% upside from AURA’s last price of $8.92) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

AURA Price Target

The average price target for Aura Biosciences (AURA) is $24.75 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $22.00. This represents a potential 177.47% upside from AURA's last price of $8.92.

AURA Analyst Ratings

Buy

According to 5 Wall Street analysts, Aura Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for AURA stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Aura Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 18, 2024George FarmerScotiabank$23.00$10.29123.52%157.85%
Oct 18, 2024Ed White IIH.C. Wainwright$22.00$10.29113.80%146.64%
Oct 18, 2024Julian HarrisonBTIG$24.00$10.29133.24%169.06%
Jul 25, 2024Edward WhiteH.C. Wainwright$21.00$9.27126.54%135.43%
Nov 11, 2022-JMP Securities$30.00$12.95131.66%236.32%
Row per page
Go to

The latest Aura Biosciences stock forecast, released on Oct 18, 2024 by George Farmer from Scotiabank, set a price target of $23.00, which represents a 123.52% increase from the stock price at the time of the forecast ($10.29), and a 157.85% increase from AURA last price ($8.92).

Aura Biosciences Price Target by Period

1M3M12M
# Anlaysts-34
Avg Price Target-$23.00$22.50
Last Closing Price$8.92$8.92$8.92
Upside/Downside-100.00%157.85%152.24%

In the current month, the average price target of Aura Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aura Biosciences's last price of $8.92. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024Cowen & Co.BuyBuyHold
Oct 18, 2024ScotiabankOutperformOutperformHold
Oct 18, 2024ScotiabankSector OutperformSector OutperformHold
Oct 18, 2024H.C. WainwrightBuyBuyHold
Oct 18, 2024BTIGBuyBuyHold
Sep 13, 2024H.C. WainwrightBuyBuyHold
Sep 13, 2024JMP SecuritiesOutperformOutperformHold
Sep 12, 2024Cowen & Co.BuyBuyHold
Jul 25, 2024H.C. Wainwright-BuyInitialise
Nov 11, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Row per page
Go to

Aura Biosciences's last stock rating was published by Cowen & Co. on Oct 18, 2024. The company gave AURA a "Buy" rating, the same as its previous rate.

Aura Biosciences Financial Forecast

Aura Biosciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Aura Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AURA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Aura Biosciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict AURA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aura Biosciences's previous annual EBITDA (undefined) of $NaN.

Aura Biosciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-26.16M$-25.16M$-24.17M$-23.18M$-22.20M$-21.90M$-22.30M
High Forecast$-26.16M$-25.16M$-24.17M$-21.85M$-21.69M$-21.90M$-22.30M
Low Forecast$-26.16M$-25.16M$-24.17M$-24.83M$-23.23M$-21.90M$-22.30M
Surprise %-------

Aura Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AURA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Aura Biosciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Aura Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AURA last annual SG&A of $NaN (undefined).

Aura Biosciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.53$-0.51$-0.49$-0.47$-0.45$-0.44$-0.45
High Forecast$-0.53$-0.51$-0.49$-0.44$-0.44$-0.44$-0.45
Low Forecast$-0.53$-0.51$-0.49$-0.50$-0.47$-0.44$-0.45
Surprise %-------

According to undefined Wall Street analysts, Aura Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AURA previous annual EPS of $NaN (undefined).

Aura Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ALXOALX Oncology$1.23$24.501891.87%Buy
ANTXAN2 Therapeutics$1.06$8.75725.47%Buy
AVTEAerovate Therapeutics$2.67$13.00386.89%Hold
OPTOpthea$3.26$14.00329.45%Buy
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
ACRVAcrivon Therapeutics$6.38$21.83242.16%Buy
BCABBioAtla$1.50$5.00233.33%Buy
CCCCC4 Therapeutics$4.15$13.50225.30%Buy
IMTXImmatics$7.81$22.00181.69%Buy
AURAAura Biosciences$8.92$24.75177.47%Buy
RZLTRezolute$4.95$13.50172.73%Buy
CGEMCullinan Oncology$13.10$31.50140.46%Buy
ADAGAdagene$2.22$5.00125.23%Buy
ORICORIC Pharmaceuticals$8.89$17.0091.23%Buy
CRNXCrinetics Pharmaceuticals$55.17$70.1427.13%Buy

AURA Forecast FAQ

Is Aura Biosciences a good buy?

Yes, according to 5 Wall Street analysts, Aura Biosciences (AURA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of AURA's total ratings.

What is AURA's price target?

Aura Biosciences (AURA) average price target is $24.75 with a range of $22 to $30, implying a 177.47% from its last price of $8.92. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Aura Biosciences stock go up soon?

According to Wall Street analysts' prediction for AURA stock, the company can go up by 177.47% (from the last price of $8.92 to the average price target of $24.75), up by 236.32% based on the highest stock price target, and up by 146.64% based on the lowest stock price target.

Can Aura Biosciences stock reach $13?

AURA's average twelve months analyst stock price target of $24.75 supports the claim that Aura Biosciences can reach $13 in the near future.

What are Aura Biosciences's analysts' financial forecasts?

Aura Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-66.409M (high $-65.893M, low $-67.442M), average SG&A $0 (high $0, low $0), and average EPS is $-1.338 (high $-1.328, low $-1.359). AURA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-98.666M (high $-97.341M, low $-100M), average SG&A $0 (high $0, low $0), and average EPS is $-1.987 (high $-1.96, low $-2.02).